|
GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.50 No.3 >
このアイテムの引用には次の識別子を使用してください:
http://hdl.handle.net/10564/517
|
タイトル: | C型慢性肝炎に対するインターフェロン療法の治療成績(Ⅱ) |
その他のタイトル: | A TRIAL OF INTERFERON TREATMENT FOR CHRONIC HEPATITIS C |
著者: | 上田, 重彦 城井, 啓 吉川, 佳嗣 安, 辰一 鎌田, 修 松下, 和広 山根, 佳子 池中, 康英 伯者, 徳之 簗瀬, 公嗣 山尾, 純一 菊池, 英亮 栗山, 茂樹 福居, 健一 植村, 正人 松村, 雅彦 高谷, 章 福井, 博 吉川, 正英 中野, 博 |
キーワード: | interferon chronic hepatitis C |
発行日: | 1999年6月30日 |
出版者: | 奈良医学会 |
引用: | Journal of Nara Medical Association Vol.50 No.3 p.215-219 |
抄録: | Interferon (IFN) is the only drug that has been approved by the FDA for
therapy of chronic hepatitis C. We conducted a trial of IFN therapy for chronic hepatitis
C. Eighty-eight patients with chronic hepatitis C were enrolled for the IFN trial. Either
9 million units (MU) of recombinant IFN α-2a (rIFN) or 6 MU of Iymphoblastoid IFNα
(nIFN) was administered daily for 4 weeks and then three times a week for 22 weeks. IFN
therapy was interrupted in 11 patients due to adverse reaction to IFN. In addition, a course
of observation including blood sampling was not enough to analyze IFN response in 21
subjects. Therefore, IFN response was evaluated in the remaining 56 patients. Complete
response (CR), defined as sustained normalization of serum transaminase values for more
than 6 months after the treatment, was obtained in 18 (32.1%). The CR rate in the present
IFN trial did not differ significantly from that (28.4%) in our previous IFN trial which
either 9 MU of rIFN or 3 MU of nIFN was administered daily for 2 weeks and then three
times a week for 22 weeks, suggesting that an increase in the total dose of interferon failed
to yield further benefit in patients with chronic hepatitis C. |
URI: | http://hdl.handle.net/10564/517 |
ISSN: | 13450069 |
出現コレクション: | Vol.50 No.3
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|